文献速递妇科肿瘤

验证2023年FIGO分期系统在子宫内膜癌患者中的预后精确性——三个ESGO认证中心的国际汇总分析

Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients - An international pooled analysis of three ESGO accredited centres.
PubMed 文献 · Eur J Cancer · 2023-09-01

该国际汇总回顾性研究纳入三个ESGO认证中心519例子宫内膜癌患者,比较2009与2023 FIGO分期的预后精确性。143例(27.6%)发生分期迁移。2023分期对无进展生存和总生存的预测更准确,早期新亚组提供额外预后信息。

要点

  • 143/519例(27.6%)发生分期迁移,其中上调123例(23.7%),下调20例(3.9%)。
  • 2023分期I期5年PFS为93.0%,2009分期为87.4%;III期分别为44.4%与54.1%。
  • 所有统计检验证实2023 FIGO分期对PFS和OS的预测更准确。

核心结论

  • 2023 FIGO分期系统使约四分之一患者发生显著分期迁移,提高了预后精确性。
  • 早期疾病中,新亚组增加了预后粒度并识别出治疗相关亚组。

研究设计与样本

  • 国际汇总回顾性研究,纳入519例子宫内膜癌患者,来自奥地利和意大利的三个ESGO认证中心,接受原发治疗并进行了分子分型。
  • 患者按2009和2023 FIGO分期系统分类,分析分期迁移,计算并比较(亚)分期特异性5年无进展生存率和总生存率。

主要发现

  • (亚)分期迁移发生于143/519例(27.6%):上调123例(23.7%),下调20例(3.9%)。
  • 2023 FIGO分期I期5年PFS率为93.0%,2009分期为87.4%。
  • 2023 FIGO分期II期5年PFS率为70.2%,2009分期为71.2%。
  • 2023 FIGO分期III期5年PFS率为44.4%,2009分期为54.1%。
  • 2023 FIGO新分子亚分期IAmPOLEmut和IICmp53abn在早期疾病中分别显示特别有利和不利的肿瘤学结局。

关键数值与推荐

  • 所有应用的统计检验证实2023 FIGO分期系统对PFS和OS的预测比2009系统更准确。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recently, the new 2023 International Federation of Gynecology and Obstetrics (FIGO) staging system for endometrial cancer (EC) critically integrating new pathological and molecular features was published. The present study evaluated the clinical impact of the new 2023 FIGO staging system by comparing it to the previous 2009 system. METHODS: This is an international, pooled retrospective study of 519 EC patients who underwent primary treatment (and molecular characterisation) at three European Society of Gynaecological Oncology (ESGO) accredited centres in Austria/Italy. Patients were categorised according to the 2009 and the 2023 FIGO staging systems. Stage shifts were analysed and (sub)stage specific 5-year progression-free (PFS) and overall survival (OS) rates were calculated and compared. Different statistical tests were applied to evaluate the prognostic precision of the two FIGO staging systems and to compare them to each other. RESULTS: (Sub)stage shifts occurred in 143/519 (27.6%) patients: 123 upshifts (23.7%) and 20 (3.9%) downshifts. 2023 FIGO staging system identified a stage I cohort with a notably higher 5-year PFS rate compared to 2009 (93.0% versus 87.4%, respectively). For stage II disease, the 5-year PFS rate was similar in the 2023 and the 2009 FIGO staging systems (70.2% versus 71.2%, respectively). The two new molecularly defined 2023 FIGO substages IAmPOLEmut and IICmp53abn displayed distinct, particularly favourable and adverse oncologic outcomes within early stage disease, respectively. A remarkably lower 5-year PFS rate for stage III patients was revealed in the 2023 FIGO staging system compared to 2009 (44.4% versus 54.1%, respectively). All applied statistical tests confirmed a more accurate prediction of PFS and OS by the 2023 FIGO staging system compared to 2009. CONCLUSION: The new 2023 FIGO stating system led to a substantial stage shift in about one quarter of patients leading to a higher prognostic precision. In early stage disease, the new substages added further prognostic granularity and identified treatment relevant subgroups.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Schwameis R, Fanfani F, Ebner C, et al. Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients - An international pooled analysis of three ESGO accredited centres. Eur J Cancer. 2023. PMID: 37748967. doi:10.1016/j.ejca.2023.113317

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。